| 000 | 01342 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250513114653.0 | ||
| 264 | 0 | _c19970509 | |
| 008 | 199705s 0 0 eng d | ||
| 022 | _a0340-7004 | ||
| 024 | 7 |
_a10.1007/s002620050355 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoth, W | |
| 245 | 0 | 0 |
_aImmunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. _h[electronic resource] |
| 260 |
_bCancer immunology, immunotherapy : CII _cMar 1997 |
||
| 300 |
_a55-63 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 |
_aBrain Neoplasms _xtherapy |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aGlioma _xtherapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xmetabolism |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xmetabolism |
| 650 | 0 | 4 |
_afas Receptor _xtherapeutic use |
| 700 | 1 | _aFontana, A | |
| 700 | 1 | _aTrepel, M | |
| 700 | 1 | _aReed, J C | |
| 700 | 1 | _aDichgans, J | |
| 700 | 1 | _aWeller, M | |
| 773 | 0 |
_tCancer immunology, immunotherapy : CII _gvol. 44 _gno. 1 _gp. 55-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002620050355 _zAvailable from publisher's website |
| 999 |
_c9093272 _d9093272 |
||